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Background: Gene expression profiling (GEP) is increasingly used in the rapidly evolving field of personalized
medicine. We sought to evaluate the association between GEP-assessed of breast cancer recurrence risk and
patients’ well-being.
Methods: Participants were Dutch women from 10 hospitals being treated for early stage breast cancer who were
enrolled in the MINDACT trial (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid
ChemoTherapy). As part of the trial, they received a disease recurrence risk estimate based on a 70-gene signature
and on standard clinical criteria as scored via a modified version of Adjuvant! Online. \Women completed a
questionnaire 6–8 weeks after surgery and after their decision regarding adjuvant chemotherapy. The questionnaire
assessed perceived understanding, knowledge, risk perception, satisfaction, distress, cancer worry and health-related
quality of life (HRQoL), 6–8 weeks after surgery and decision regarding adjuvant chemotherapy.
Results: Women (n = 347, response rate 62%) reported high satisfaction with and a good understanding of the GEP
information they received. Women with low risk estimates from both the standard and genomic tests reported the
lowest distress levels. Distress was higher predominately among patients who had received high genomic risk
estimates, who did not receive genomic risk estimates, or who received conflicting estimates based on genomic
and clinical criteria. Cancer worry was highest for patients with higher risk perceptions and lower satisfaction.
Patients with concordant high-risk profiles and those for whom such profiles were not available reported lower
quality of life.
Conclusion: Patients were generally satisfied with the information they received about recurrence risk based on
genomic testing. Some types of genomic test results were associated with greater distress levels, but not with
cancer worry or HRQoL.
Trial registration: ISRCTN: ISRCTN18543567
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ChemotherapyBackground
Gene expression profiling, an example of personalized
medicine, has moved quickly into clinical care. Breast
cancer treatment guidelines that incorporate genomic
testing include those from the National Comprehensive
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reproduction in any medium, provided the orClinical Oncology (ASCO), the 2008 Dutch Clinical
Guidelines (CBO) and the 2009 St Gallen guidelines [1].
One gene expression test is the 70-gene signature
(Mamma-Print™) [2,3] that can accurately distinguish
early stage breast tumours at high risk for distant
metastasis from low-risk tumours. Several retrospective
validation studies have confirmed its prognostic value
[4-6], though the effects of receiving results from this test
on patient well-being are largely unknown.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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array In Node-negative and 1 to 3 positive lymph node
Disease may Avoid ChemoTherapy; EORTC 10041/BIG
3–04) evaluated prospectively whether the 70-gene
signature selects the right patients for adjuvant chemo-
therapy better than standard clinicopathological criteria
[7,8]. This trial enrolled 6700 early stage breast cancer
patients throughout Europe, who had their risk of disease
recurrence assessed by both standard clinicopathological
criteria and the 70-gene signature. Clinicopathological
prognostic risk was assessed through a modified version
of Adjuvant! Online [9]. Low risk for distant recurrence
was defined as >88% chance of 10-years survival for
oestrogen receptor (ER)-positive breast cancer and >92%
for ER-negative breast cancer. Concordant genomic
high (G-high) and clinicopathological high (C-high) risk
patients were recommended to undergo adjuvant
chemotherapy, and concordant G-low and C-low risk
patients were informed that chemotherapy is not
recommended. Discordant patients (“C-low/G-high”
of “C-high/G-low”) were randomized to treatment-
decision making based on the genomic risk assessment
or treatment-decision making based on the clinical risk
assessment [10].
Since genomic testing is a recent development, rela-
tively few studies have investigated psychosocial issues
surrounding these tests. O’Neill et al., in a survey of 139
women who received breast cancer treatment before
genomic profiling was available, found a strong interest
in genomic testing [11]. Richman et al., in a study of 78
breast cancer patients who had previously received gene
expression profiling, reported that many women had an
inadequate understanding of gene profiling [12]. In an
analysis of data from the same study, Tzeng et al. found
that many breast cancer patients preferred a level of
shared decision making that was different from what
they experienced with their doctors [13]. Lo et al. found
that receiving gene expression profiling results lowered
patients’ (n = 89) anxiety [14]. Both Tzeng et al. and Lo
et al. found that patients’ decisions were largely concordant
with their gene expression profile results. These studies
tended to have small samples, examined the effects of
different risk results only minimally, and did not investigate
the impact of the combination of gene profiling and
clinical risk data in their analyses. Recently, Sulayman
et al. reported on the psychosocial and quality of life
impact of women receiving an intermediate genomic
score [15]. They found that those women who took a
passive role in their care reported higher cancer-related
distress and cancer worry and lower quality of life than
those who took a shared or active role [15].
The primary aims of our study were to evaluate the
association between breast cancer patients’ well-being
and the results of a gene expression profile on tocompare different recurrence risk groups, according to
their genomic and standard clinical risk assessments.
We expected higher well-being for the concordant “C-low/
G-low” risk group (clinical and genomic assessments
indicate low risk), lower well-being in patients who did
not receive genomic results and lower well being for
the discordant “C-low/G-high” risk groups (clinical
parameters indicate low risk while genomic test indicates
high risk), especially the group who did not receive
chemotherapy. In addition, we examined the extent to
which women understood the genomic test information
received, risk perception, knowledge, and satisfaction with
provided information and with the clinical process.
Methods
Study sample
Women taking part in the MINDACT-trial from 10
hospitals in the Netherlands were approached to participate
in the study. Eligible patients were those with early stage
breast cancer (0–3 positive lymph nodes) who were able
to read and write in Dutch or English. In addition to the
patients enrolled in the MINDACT trial, we also included
in our sample women screened for MINDACT trial
inclusion, but who ultimately were found ineligible
because their genomic results were unavailable (i.e.,
samples had >3 positive lymph nodes (62%), or insufficient
RNA quality or logistical problems (38%)) [10]. The latter
occurred primarily during the first period of the study, but
decreased thereafter. Clinical tests (C) had two possible
results (low or high recurrence risk) and genomic tests
(G) had three (low, high or a “not available” (na) recurrence
risk). Crossing clinical and genomic results, and accounting
for trial assignment of discordant test results, yielded 8
groups: 1) “C-low/G-low”, 2) “C-high/G-high”, 3) “C-low/
G-high assigned to no CT”, 4) “C-low/G-high assigned to
CT”, 5) “C-high/G-low assigned to no CT”, 6) “C-high/
G-low assigned to CT”, 7) “C-low/G-na”, and 8) “C-high/
G-na”. This study received review and approvals from the
Central Review Board of the University of Maastricht,
institutional review boards of the Netherlands Cancer
Institute and participating hospitals, the European Orga-
nization for Research and Treatment of Cancer Protocol
Review Committee, the TRANSBIG and MINDACT
Steering Committees and the TRANSBIG Ethical-Legal
Committee.
Procedures
Patient recruitment began in September, 2008 and
continued until the end of August, 2010. Eligible patients
received an invitation letter signed by the treating
physician, along with the general MINDACT-trial
information before surgery. Patients who were enrolled in
the MINDACT trial could choose whether to participate
in the current study. Patients had surgery to remove their
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questionnaire accompanied by an informed consent form.
At the time we sent the questionnaires, patients had
received assessments of their risk for breast cancer recur-
rence from the standard clinical markers and the genomic
profile and had made a decision regarding adjuvant treat-
ment, but they had not yet started adjuvant treatment.
Patients who did not respond to the initial invitation were
mailed a reminder two weeks later (See Figure 1). All
study materials were in Dutch.
Measures
During a previous feasibility study, the MicroarRAy
PrognoSTics in Breast CancER (RASTER) study [16], we
interviewed 27 patients about their personal experiences
dealing with the 70-gene signature. Based on these
interviews, we constructed a questionnaire and pilot
tested it with 77 patients in the same study [17]. A
modified version of this questionnaire was used in
the current study (See for the total questionnaire
Additional file 1).
The questionnaire assessed sociodemographic, clinical
and psychosocial variables. The primary study outcomeEligible pa
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Figure 1 CONSORT diagram.was patient well–being, defined as genomic testing-specific
distress (referred to subsequently as distress), cancer-
specific worry, and health-related quality of life (HRQoL).
Distress was assessed with 10 items adapted from Lynch’s
distress scale [18] (α = 0.91). An adapted 7-item version of
Lerman’s Cancer Worry Scale [19] (α = 0.89) was used to
measure cancer worry. The Breast Cancer Subscale of
the Functional Assessment of Cancer Therapy – Breast
questionnaire was used to assess HRQoL [20]. We
averaged items for each scale to create 3 continuous
composite variables.
The questionnaire also measured variables that could
have influenced the way patients responded to their test
results, as shown in Table 1. We developed 5 items
regarding the extent to which women understood the
information provided (α = 0.81): 1 item on whether women
received both test results at the same or at separate
medical visits; 14 items on genomic test knowledge,
scored for accuracy and summed to form a “knowledge”
index; 1 item on perceived risk of breast cancer
recurrence; and 5 items on satisfaction with provided
information and process, averaged to form a “satisfaction”
scale (α = 0.78).tients
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Table 1 Questionnaire measures
Predictor variables No. of items (response scale) α* Mean (SD) Item wording (translated from Dutch)
Perceived understanding 5 items (4-point scale) 0.81 2.89 (0.42) Did you find the verbal information clear?
Did you find the written information clear?
Did you find the information prior to the test clear?
Did you find the information about handling the
results clear?
Did you find the total information clear, for making
a careful decision?
Results received at the same visit 1 item (Yes/no) NA Did you receive the test results on one occasion?
Knowledge 14 items (Yes, no, DK) 75% (0.17) See Table 3
Risk perception 1 item (0-100%) NA What do you think is the chance your cancer will
come in the coming 10 years?
Satisfaction 5 items (5-point scale) 0.78 2.06 (0.65) How satisfied were you with the total medical care
for breast cancer; with the time you had to wait for
the test results; the total information provided; the
way the results were conveyed; communication
with the medical and nursing staff.
Outcomes
Distress 10 items (4-point scale;
a little, some, very, a lot)
0.91 1.99 (0.79) How did you feel when your doctor told you the
[genomic] test results? relieved, glad, disappointed;
sad; surprised; confused; upset; insecure; angry;
helpless; anxious; guilty; sombre.
Cancer-specific worry 7 items (4-point scale) 0.89 1.79 (0.58) During the last 4 weeks: how often have you
thought about getting cancer again; how often
do you worry about getting metastasis; needing
chemotherapy again; did this affect your mood?
Quality of life 9 items (5 point scale) 0.63 26.44 (5.11) Breast cancer subscale of the FACT-B
*Cronbach’s alpha in the present study.
DK, don’t know; NA, not applicable.
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We imputed values for 61 patients with missing data
(17.5%, mostly in the well-being scales), assuming that
data are missing at random. The procedure relied on
variables in the regression analysis and variables predictive
of missing values to create five complete datasets after 100
iterations using fully conditional specification [21]. Mul-
tiple imputation is currently regarded as a state-of-the-art
technique because it improves accuracy and statistical
power relative to other missing data techniques (including
list wise deletion). We conducted analyses with each of the
five datasets and then pooled results according to Rubin’s
rules [22]. As the analysis of the original dataset without
imputation yielded the same pattern of findings, and the
imputation set is more efficient with more data, we only
report results from the imputation dataset in the
results.
We assessed baseline differences between groups with
Student’s t-test, the Mann Whitney-U test, and chi-
square tests. We used unadjusted univariate analysis of
variance (ANOVA) to evaluate whether the risk groups
differed in distress, worry and HRQoL. Block-wise mul-
tiple linear regression analysis was carried out toidentify variables associated with distress, worry and
HRQoL. The first block contained the sociodemographic
variables; the second block contained relevant additional
factors such as understanding, risk perception, satisfac-
tion, knowledge and receiving both tests on one occasion;
the third block contained the genomic test result risk
group variables. The “C-low/G-low” group was the refer-
ence category. In the regression analysis, the residuals
were checked for normality. The R2 was calculated
according to the formula in Harel, 2009 [21]. In order
to maintain the family-wise Type 1 error at 0.05 over
the multiple (correlated) tests, we set the critical alpha
at a conservative 0.01. We conducted all analyses with
SPSS version 17, except Rubin’s rules, for which we
used version 18.
Results
Study sample
Of 566 patients we invited to participate, 347 returned
completed questionnaires (62% response rate; see
Figure 1). The characteristics of respondents are shown in
Table 2. On average, we received the questionnaires within
3 months (89 days) of sending them. In general, guidelines
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surgery, women should start radiotherapy that takes add-
itional 7 weeks (49 days). Thus, on average respondents
would not yet have started (possible) chemotherapy at the
time they completed the survey. Concordant risk results
were the most common finding: “C-low/G-low” (n = 111)
and “C-high/G-high” (n = 72). Discordant risk results
were the least common: “C-low/G-high assigned to no
CT” (n = 12), “C-low/G-high assigned to CT” (n = 18),
“C-high/G-low assigned to no CT” (n = 25), and “C-high/
G-low assigned to CT” (n = 25). Genomic results deemed
“not available” were also found: “C-low/G-na” (n = 33) and
“C-high/G-na” (n = 56).Table 2 Characteristics of respondents (N = 347)
n % Mean (range) SD
Age 55,3 (26–71) 8.8
≤35 10 3
36-45 37 11
46-55 119 34
56-65 139 40
≥66 42 12
Marital status
Living as married 274 79
Not living as married 73 21
Had children
Yes 274 79
No 73 21
Education
Primary school 46 13
High school 192 55
College or university 109 32
Dutch citizen
Yes 325 94
No 22 6
Relatives who underwent CT before
Yes 152 44
No 189 55
Recurrence risk group
C-low/G-low 109 31
C-high/G-high 70 20
C-low/G-high assigned to no CT 12 4
C-low/G-high assigned to CT 17 5
C-high/G-low assigned to no CT 25 7
C-high/G-low assigned to CT 25 7
C-low/G-na 33 10
C-high/G-na 56 16
Note. C, clinical, G, genomic, CT, chemotherapy. Analyses that included age
treated it as a continuous variable.Perceived understanding of the test information
Few women (n = 21, 6%) had heard of the 70-gene signa-
ture before their diagnosis. Women recalled that they
had received information about their risk of metastasis
most often in words (n = 139, 43%), less commonly in
both words and numbers (n = 100, 31%), and rarely in
numbers only (n = 25, 8%); the remaining patients did
not respond to this question. In general, women found
the information they received to be understandable: the
written information was perceived as clear by 87% of the
women, verbal information by 87%, information prior to
the test results by 85%, information about adjuvant
treatment by 82%, and information necessary to make a
careful decision by 83%. Twenty-seven percent of the
women received both test results at the same medical
visit (on average two weeks after surgery); 71% received
them on two successive occasions (clinical assessment
on average one week after surgery, and GEP results on
average two weeks after surgery); and for the remaining
2% this was unknown.Knowledge and perceived risk
Knowledge about genomic recurrence risk testing was rela-
tively high (mean correct answers, across 14 items = 75%)
(Tables 3 and 4). Two questions that elicited substantially
more “I don’t know” responses were “The result of the
genomic profile is always correct” (43% don’t know); “For
a breast tumour with a high risk genomic profile, the
chance of metastasis in the next 10 years is 50%” (53%
don’t know). The three questions with the most incorrect
answers were: “A high genomic profile indicates that a
patient will need to have her lymph nodes removed”
(25%); “The genomic profile indicates the chance of
metastasis” (23%); and “For a breast tumour that the
genomic profile indicates as high risk, the chance of
metastasis in the next 10 years is 50%” (20%). Women
with relatives who previously underwent chemotherapy
answered more questions correctly (on average 78%
versus 73% correct answers p = 0.006). On average, patients
perceived their risk of recurrence to be 26.6%.Satisfaction
Almost all women (97%) were satisfied with their experi-
ence from diagnosis up to the time that the questionnaire
was completed. Similarly, 94% expressed overall satisfac-
tion with the information received. Twenty-eight percent
of the patients were unsatisfied with the waiting time for
the results. Based on self-report data, 6% received results
within 1 week of surgery, 23% within 2 weeks, 29% within
3 weeks, 23% within 4 weeks, and 18% after more
than 4 weeks. Nine percent of the patients expressed
dissatisfaction with the way in which doctors conveyed
the results (Table 4).
Table 3 Knowledge (N = 347)
Correct Incorrect I don’t know
(%) (%), (%)
Correct answer was “true”
The GP is done on tumour tissue from the breast removed by surgery. 97 1 2
The GP is based on the genes of the breast tumour. 90 4 6
The GP help some women avoid having unneeded chemotherapy. 90 4 6
A patient with a high risk tumour will be recommended chemotherapy. 86 5 9
The GP gives the chance of metastasis. 67 23 10
For a high risk tumour, the chance of metastasis in the next 10 years is over 50%. 27 21 52
Correct answer was “false”
The GP is done before surgery that removes the tumour. 88 6 6
Only the GP is used by the doctor to recommend chemo. 88 6 6
A GP tells whether other women in the family have higher risk of breast cancer. 78 11 11
The GP tells whether cancer cells have spread to the lymph nodes. 74 18 8
The GP can help women to decide about the sort of breast cancer surgery to undergo. 70 17 13
The GP looks at all genes in a patient’s body. 69 14 17
A high risk GP indicates that a patient will need to have lymph nodes removed. 62 25 13
The GP is always correct. 38 19 43
Note. GP, genomic profile.
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In the unadjusted (univariate) analysis, distress was
different among the risk groups (p = 0.017) (Figure 2,
Table 5). In the adjusted (regression) analysis, risk
group remained associated with distress levels after
controlling for sociodemographic, information/knowledge,
and risk perception variables (Table 6). The group “C-low/
G-low” (reference) reported the lowest distress, not
different from the group “C-high/G-low assigned to
chemotherapy” (p = 0.18). Associated with higher distress
compared to the reference group were the groups:
genomic profile not available (p = 0.002 and p < 0.001),Table 4 Mean satisfaction, perceived understanding, knowled
Satisfaction Perceived u
(95% CI) (95
C-low/G-low 2.02 (1.92-2.13) 2.91 (
C-high/G-high 2.08 (1.92-2.24) 2.94 (
C-low/G-high (ass. no CT) 2.23 (1.70-2.77) 2.65 (
C-low/G-high (ass. CT) 2.15 (1.82-2.49) 2.88 (
C-high/G-low ass. no CT 2.08 (1.78-2.38) 2.88 (
C-high/G-low (ass.CT) 1.97 (1.63-2.31) 2.94 (
Overall 2.06 (1.98-2.14) 2.90 (
p 0.831 0
Note. n = 347. The reference group in analyses was C-low/G-low; p value is for omni
chemotherapy.
Satisfaction scale: “very satisfied” (coded as 1), ”satisfied” (2), ”neutral” (3), ”unsatisfi
Perceived understanding scale : “not at all clear” (1), ”somewhat clear” (2), ”modera
Knowledge scale : percentage of correctly answered questions.
Risk perception scale: “no risk of developing metastasis within 10 years” (0),“100% r“C-high/G-high” (p = 0.01) and the discordant groups
“C-low/G-high assigned to CT” (p < 0.001) and “C-high/
G-low assigned to no CT” (p < 0.001) (Table 6).Worry
In the unadjusted analysis, the 8 risk groups had similar
levels of worry (p = 0.234) (Figure 2). In the adjusted
analysis, corrected for demographic factors, higher levels
of worry were observed among women who expressed
lower satisfaction (p < 0.001) and among women with
higher perceived risk (p < 0.001) (See Table 6).ge and risk perception
nderstanding Knowledge Risk perception
% CI) (95% CI) (95% CI)
2.84-2.98) 0.77 (0.74-0.80) 22.38 (18.28-26.48)
2.84-3.04) 0.78 (0.73-0.82) 31.60 (24.78-38.42)
2.31-2.99) 0.73 (0.59-0.86) 35.91 (20.17-51.65)
2.65-3.12) 0.77 (0.70-0.84) 30.31 (17.91-42.71)
2.69-3.08) 0.78 (0.75-0.79) 27.09 (15.43-38.74)
2.78-3.11) 0.76 (0.69-0.83) 22.05 (12.37-31.73)
2.85-2.96) 0.77 (0.75-0.79) 26.50 (23.43-29.56)
.353 0.952 0.115
bus test. C, clinical, G, genomic, ass. = randomly assigned to receive, CT,
ed” (4), ”very unsatisfied” (5).
tely clear” (3), ”completely clear” (4).
isk” (100).
Figure 2 Unadjusted analysis for Distress, Cancer worry and
Health-related quality of life (N = 347). Box plots show median
line, quartiles and outliers. C= clinical, G= genomic, Ass= assigned
to, CT= chemotherapy.
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In the unadjusted analysis, HRQoL was different among
the risk groups (p = 0.024) (Figure 2). In the adjusted
analysis, older age was associated with better HRQoL
(p < 0.001), while higher risk perception was associated
with lower HRQoL (p < 0.001). After controlling for
demographic and process factors, only the “C-high/G-na”
(p < 0.001) risk group reported lower HRQoL compared
to the reference group “C-low/G-low” (See Table 6).Discussion
In general, women indicated that the information they
received regarding the test results was clear and satisfac-
tory and resulted in a good understanding of the genomic
profile and its consequences. As expected, we found the
least distress among patients with a low recurrence risk
according to standard and genomic indicators. Most other
groups had statistically significant or marginally higher
distress except for patients with high risk according to
clinical indicators, low recurrence risk according to the
genomic profile and assigned to chemotherapy. Our
expectation that higher distress, more worry and lower
HRQoL would be observed among the discordant “C-low/
G-high” risk groups was not confirmed. Rather, higher
distress levels compared to the reference group were
observed for the “C-low/G-high assigned to chemotherapy”
and “C-high/G-low not assigned to chemotherapy”.
Higher distress among patients with uniformly high risk
results or with uncertain genomic results makes intuitive
sense. Patients with discordant results appear to have had
a lingering sense of unease. They may have derived
comfort from receiving chemotherapy together with a low
genomic risk result. However, either one on its own
appears to have been insufficient to ameliorate women’s
distress. In the future, the genomic risk profile results may
become incorporated into clinical guidelines, such that
patients would receive only one test outcome, which could
help to reduce uncertainty and distress.
Although we expected high correlations among the
three study outcomes (distress, worry and quality of life),
they were only moderately correlated. Furthermore,
we found distinct correlates of each. Distress levels
tended to vary primarily as a function of risk group,
whereas worry was associated with risk perception
and satisfaction. Lower quality of life was associated
with younger age, higher perceived risk, and the risk
group with “C-high/G-na” result. These differences
may be due, in part, to the varying focus of these
three measures. The distress scale assesses primarily
distress related to the genomic results, while the
worry scale assesses breast cancer-related worry, and
the quality of life measure taps into both general and
breast cancer-related issues.
Table 5 Accompanying Figure 2
Distress Worry Quality of life
Mean (95% CI) Mean (95% CI) Mean (95% CI)
C-low/G-low 1.52 (1.42 to 1.62) 1.73 (1.63 to 1.84) 28.0 (27.1 to 28.9)
C-high/G-high 2.39* (2.21 to 2.56) 1.82 (1.69 to 1.95) 25.6* (24.4 to 26.9)
C-low/G-high (assigned to no CT) 2.03* (1.64 to 2.41) 1.77 (1.41 to 2.14) 28.0 (24.9 to 31.1)
C-low/G-high (assigned to CT) 2.71* (2.35 to 3.07) 1.72 (1.40 to 2.05) 26.3 (23.6 to 29.0)
C-high/G-low (assigned to no CT) 2.11* (1.70 to 2.52) 1.85 (1.61 to 2.10) 26.9 (24.6 to 29.1)
C-high/G-low (assigned to CT) 1.68 (1.45 to 1.91) 1.49 (1.34 to 1.65) 26.9 (25.1 to 28.8)
C-low/G-na 1.95* (1.58 to 2.32) 1.86 (1.61 to 2.10) 26.0 (23.9 to 28.2)
C-high/G-na 2.31* (2.11 to 2.51) 1.95 (1.80 to 2.11) 23.8* (22.5 to 25.2)
Note. The reference group in analyses was C-low/G-low. C, clinical, G = genomic, CT, chemotherapy, na, result not available. n = 347.
*p < 0.01.
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pared to previous studies, its multicenter and prospective
research design, and the use of standardized measures
to assess psychosocial outcomes. The distribution of
patients across the subgroups and the general characteristics
of the sample were comparable to those of the predefined
pilot phase of the MINDACT trial [10].Table 6 Correlates of distress, worry and quality of life in adj
Distress
b (se) p
Block 1
Age −0.001 (0.005) 0.821
Married −0.046 (0.099) 0.645
Had children 0.124 (0.097) 0.203
Primary school (vs. High school) −0.018 (0.126) 0.885
College (vs. High school) −0.185 (0.088) 0.036
Block 2
Understanding −0.199 (0.113) 0.079
Results received in 1 visit −0.016 (0.085) 0.849
Knowledge −0.021 (0.014) 0.137
Risk perception 0.003 (0.002) 0.128
Satisfaction 0.151 (0.071) 0.032
Block 3
C-high/G-high 0.877 (0.105) 0.000*
C-low/G-high (assigned to no CT) 0.423 (0.209) 0.043
C-low/G-high (assigned to CT) 1.115 (0.178) 0.000*
C-high/G-low (assigned to no CT) 0.611 (0.153) 0.000*
C-high/G-low (assigned to CT) 0.221 (0.163) 0.175
C-low/G-na 0.488 (0.152) 0.002*
C-high/G-na 0.710 0.126) 0.000*
Note. b = unstandardized pooled regression coefficient, se = standard error, C = clini
for recurrence risk groups was C-low/G-low.
Distress: Block 1 R2 = 0.040 Block 2 R2 = 0.147; Block 3: R2 = 0.385.
Worry: Block 1 R2 = 0.039 Block 2 R2 = 0.228; Block 3: R2 = 0.251.
Quality of Life: Block 1 R2 = 0.094 Block 2 R2 = 0.156; Block 3 R2 = 0.219.
*p < .01.The study also had several limitations. First, while we
were able to form 8 groups on the basis of clinical and
genomic risk status and treatment decision, the groups
with discordant risk estimates were relatively small, and
thus may have limited the power of the study to detect
group differences. This may explain, in part, why we did
not confirm the hypothesis that the “C-low/G-highusted analyses
Worry Quality of life
b (se) p b (se) p
−0.042 (0.021) 0.049 0.122 (0.034) 0.000*
0.647 (0.422) 0.125 1.165 (0.680) 0.087
−0.089 (0.442) 0.841 −1.566 (0.689) 0.023
−0.307 (0.583) 0.598 −1.864 (0.869) 0.032
−0.125 (0.407) 0.759 0.243 (0.639) 0.703
−0.963 (0.497) 0.052 −0.119 (0.756) 0.875
−0.224 (0.378) 0.554 0.187 (0.593) 0.753
−0.127 (0.056) 0.023 0.109 (0.086) 0.203
0.049 (0.008) 0.000* −0.043 (0.012) 0.000*
0.852 (0.323) 0.008* −0.517 (0.481) 0.282
0.107 (0.494) 0.827 −1.908 (0.769) 0.013
−1.085 (0.962) 0.259 0.793 (1.453) 0.585
−0.610 (0.816) 0.455 −1.407 (1.235) 0.254
0.435 (0.706) 0.538 −0.671 (1.099) 0.541
−1.230 (0.705) 0.081 −1.131 (1.081) 0.296
0.427 (0.651) 0.512 −1.752 (0.984) 0.075
0.842 (0.527) 0.111 −3.816 (0.824) 0.000*
cal, G = genomic, CT = chemotherapy, na = result not available. Reference group
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higher distress. The “C-low/G-low” group was chosen as
the reference category, because we were not able to
compare the risk groups with patients who did not
receive or were not prepared to receive a genomic profile.
Furthermore, the results of the multivariate analysis did
not change by using only the MINDACT trial eligible
respondents (leaving out the no-genomic results group).
Second, the response rate in this study was moderate
(62%), although we would note that it is in line with that
observed in other randomized EORTC trials [23,24].
Third, we could not distinguish the difference between the
genomic or clinical low group separately, because the
patients in the clinical trial were randomized directly after
the results were known. So, the effects of the various
risk profiles on well-being could not been examined
independent of the effect of the adjuvant treatment
advice. Although our study sample included both
women who had and had not been randomized into the
MINDACT trial, including these patients did not appear
to have changed our results. When we performed the
same analyses for the randomized group only, the
results were in line with those based on the combined
sample (data not shown). Finally, it could be that some
patients may have completed the survey after starting
chemotherapy, which means that there could be a small
confusion bias between the impact of the result and
undergoing chemotherapy.
Conclusion
Our results indicate that the current system of providing
genomic test results as in the MINDACT trial works well.
Women found the information they received was clear
and satisfactory and helped them understand the genomic
profile and its consequences. While these findings are
encouraging, clinicians should be aware that genomic test
results may be associated with patients’ wellbeing. Especially
for patients with high recurrence risk or discordant
risk test results, it may be advisable to offer additional
psychological counselling, as such counselling can reduce
distress associated with the results of genetic tests [25].Additional file
Additional file 1: Patient questionnaire research on the experience
of the MammaPrintTM(70-gene prognosis profile, microarray test).
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